<DOC>
	<DOCNO>NCT02398825</DOCNO>
	<brief_summary>This study aim evaluate efficacy treatment ponatinib patient chronic myeloid leukemia chronic phase previously receive treatment imatinib result resistant .</brief_summary>
	<brief_title>Activity Risk Profile Ponatinib Chronic Phase Patients With Chronic Myeloid Leukemia Resistant Imatinib</brief_title>
	<detailed_description>Phase 2 , single-arm , multicentre , open label . No interim analysis plan , monitor committee evaluate data every 6 month . Ponatinib give orally 30 mg daily , dose adjustment 15 mg daily BCR-ABL1 level small equal 0.1 % ( MMR ) achieve confirm next test , 4 week apart . A return prior , 30 mg , dose due case return BCR-ABL1 transcript level &gt; 1 % . Dose adjustment toxicity detail protocol . Treatment time 52 week , study drug provide free-of-charge ARIAD Pharmaceuticals , upon approval protocol . Treatment discontinue time case failure treatment-related SAEs . After one year treatment , upon request local investigator upon confirmation Treatment Advisory Committee ( TAC , see section 23 ) , ARIAD Pharmaceutics , Inc. continue provide ponatinib study patient benefit treatment continuation , least 2 year , drug approve indication .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Cytogenetic and/or molecular confirm diagnosis Ph+ and/or BCRABL1+ CML 2 . Age â‰¥ 18 year 3 . Chronic phase CML 4 . Prior treatment imatinib , dose 5 . Resistance imatinib , define one ELN 2013 failure criterion , follow : complete hematologic response ( CHR ) 3 month cytogenetic response ( CyR ) ( Ph+ &gt; 95 % ) 3 month Less partial CyR ( PCyR , Ph+ &gt; 35 % ) 6 month BCRABL1 &gt; 10 % 6 month Non complete CyR ( CCyR ) ( Ph+ &gt; 0 % ) 12 month BCRABL1 &gt; 1 % 12 month Loss CHR , time Loss CCyR , time Confirmed loss major molecular response ( MMR ) ( BCRABL1 big equal 0.1 % two consecutive test , one big equal 1 % ) , time Any new BCRABL1 mutation , time 6 . For female childbearing potential , negative pregnancy test must document prior enrolment 7 . An effective form contraception sexual partner enrolment 4 month end treatment 8 . Signed write informed consent accord ICH/EU/GCP national local law prior study procedure 9 . Willingness ability comply schedule visit study procedure . 1 . Accelerated blastic phase CML 2 . Patients previously treat nilotinib dasatinib 3 . Patients T315I mutation 4 . History acute pancreatitis within 1 year study history chronic pancreatitis alcohol abuse 5 . Patients history acute myocardial infarction ( AMI ) , unstable angina coronary heart disease ( CHD ) , congestive heart failure , cerebrovascular event ( CVE ) ( stroke transitory ischemic attack ) , peripheral artery occlusive disease ( PAOD ) 6 . Compelled take medication know associated Torsades de Pointes and/or significant QTc prolongation 7 . Pregnant breastfeed 8 . Any condition illness , opinion Investigator , would compromise patient safety interfere evaluation drug 9 . Lack inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>Chronic phase</keyword>
	<keyword>Adults</keyword>
	<keyword>Ponatinib</keyword>
	<keyword>Imatinib resistant</keyword>
</DOC>